Core Viewpoint - WuXi AppTec (02359) demonstrated strong performance in the first half of the year, with robust growth in revenue and net profit, alongside margin expansion and notable performance in TIDES business [1] Financial Performance - Revenue and net profit showed steady growth, with TIDES business performing exceptionally well [1] - The chemical business exhibited resilient growth, helping to offset the weakness in clinical CRO and testing services [1] Management Guidance - Management raised the 2025 revenue guidance to RMB 42.5 billion to RMB 43.5 billion, indicating a projected growth of 13% to 17% in ongoing operations [1] - Capital expenditure remains unchanged at RMB 7 billion to RMB 8 billion [1] Analyst Forecasts - Zhongyin International upgraded WuXi AppTec's earnings forecasts for the next two years by 15% and 22% respectively [1] - The target price was increased from HKD 81 to HKD 122, maintaining a "Buy" rating [1]